LEARNING OBJECTIVES

1. Evaluate pharmacotherapy for the patient awaiting left ventricular assist device (LVAD) or heart transplantation (HT).
2. Design optimal therapy for patients receiving extracorporeal membrane oxygenator support.
3. Develop effective thromboprophylactic strategies for patients receiving percutaneous ventricular assist device support.
4. Develop effective treatment for patients with complications of durable LVAD therapy.
5. Design optimal pharmacotherapy for the patient recovering from HT.

ABBREVIATIONS IN THIS CHAPTER

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACT</td>
<td>Activated clotting time</td>
</tr>
<tr>
<td>aPTT</td>
<td>Activated partial thromboplastin time</td>
</tr>
<tr>
<td>CF-LVAD</td>
<td>Continuous-flow left ventricular assist device</td>
</tr>
<tr>
<td>CMV</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>CVP</td>
<td>Central venous pressure</td>
</tr>
<tr>
<td>ECMO</td>
<td>Extracorporeal membranous oxygenation</td>
</tr>
<tr>
<td>ELSO</td>
<td>Extracorporeal Life Support Organization</td>
</tr>
<tr>
<td>HF</td>
<td>Heart failure</td>
</tr>
<tr>
<td>HT</td>
<td>Heart transplantation</td>
</tr>
<tr>
<td>IABP</td>
<td>Intra-aortic balloon pump</td>
</tr>
<tr>
<td>LV</td>
<td>Left ventricle</td>
</tr>
<tr>
<td>LVAD</td>
<td>Left ventricular assist device</td>
</tr>
<tr>
<td>MAP</td>
<td>Mean arterial pressure</td>
</tr>
<tr>
<td>MCS</td>
<td>Mechanical circulatory support</td>
</tr>
<tr>
<td>PCWP</td>
<td>Pulmonary capillary wedge pressure</td>
</tr>
<tr>
<td>pVAD</td>
<td>Percutaneous ventricular assist device</td>
</tr>
<tr>
<td>PVR</td>
<td>Pulmonary vascular resistance</td>
</tr>
<tr>
<td>RV</td>
<td>Right ventricle</td>
</tr>
<tr>
<td>VA</td>
<td>Venoarterial</td>
</tr>
</tbody>
</table>

Table of other common abbreviations.

INTRODUCTION

Despite advances in pharmacotherapy and device technology (e.g., implantable cardioverter-defibrillator and cardiac resynchronization therapy), heart failure (HF) remains a leading cause of morbidity and mortality in both the United States and around the world. This morbidity and mortality is particularly prominent with advanced HF (i.e., stage D), which carries an about 90% 1-year mortality rate without heart transplantation (HT) or left ventricular assist device (LVAD) implantation (Mehra 2012). Patients with advanced disease have disease progression and develop persistently severe symptoms at rest or with minimal activity despite conventional HF drug therapy regimens. Such advanced disease may eventually require admission to the ICU for aggressive stabilizing measures such as mechanical ventilation, fluid removal (including ultrafiltration), and intravenous inotropic therapy.

Criteria for Advanced HF

Although various criteria have been proposed to characterize advanced HF, no single diagnostic test can identify these patients. Rather, a combination of biomarkers, physical examination findings, laboratory data, and functional capacity allow for assessment of disease severity. The American College of Cardiology/American Heart Association (ACC/AHA) has defined these patients as those “with truly refractory HF who might be eligible for specialized, advanced treatment strategies, such as mechanical circulatory support (MCS), procedures to facilitate fluid removal, continuous positive inotropic infusions, or cardiac transplantation or other innovative or experimental surgical procedures, or for end-of-life care, such as hospice”
The European Society of Cardiology has created a list of objective criteria that help identify patients with advanced HF (Box 1). Clinical pharmacists should be familiar with these criteria so that they can anticipate and recommend medication-based therapies to improve symptoms and/or hemodynamics. The presence of advanced disease influences the overall goals of care and the approach to treating patients with HF. For instance, a patient with stage C disease who is admitted to the ICU with acute HF and renal injury may require a short-term course of inotrope or vasodilator-assisted diuresis, whereas a patient with stage D disease may require long-term vasoactive therapy, as a bridge to either a durable LVAD or HT.

Candidacy for LVAD and HT

The evaluation process for advanced HF treatment modalities is complex and beyond the scope of this chapter. Although international guidelines have proposed suggestions for which patients should be considered for these therapies, each institution ultimately develops its own listing criteria according to the institution’s volume and risk tolerance for managing complex patients. Table 1 has examples of common inclusion and exclusion criteria for both HT and a durable LVAD. Of note, though some prohibiting conditions are common to both options (e.g., limited life expectancy or severe pulmonary disease), others are uniquely exclusive (e.g., severe right ventricular [RV] failure would preclude a durable LVAD but not HT). In addition, some HT contraindications may improve or resolve during LVAD support (e.g., pulmonary hypertension or obesity). Patients may initially receive an LVAD as destination therapy with the plan to reevaluate their transplant candidacy later. Finally, clinical pharmacists should be mindful of the poor prognosis for patients with advanced HF who are not candidates for either HT or durable LVAD therapy and be able to guide the overall drug therapy strategy toward palliative care, should the patient be deemed ineligible for both.

**Box 1. European Society of Cardiology Definition of Advanced HF**

1. Severe symptoms of HF at rest (NYHA class IV)
2. Episodes of pulmonary or systemic congestion and/or reduced cardiac output at rest
3. Objective evidence of severe cardiac dysfunction as shown by at least one of the following: LVEF < 35%; pseudo-normal or restrictive mitral inflow pattern; mean PCWP > 16 mm Hg and/or RA pressures > 12 mm Hg; or high BNP or NT-proBNP plasma concentrations
4. Severe impairment of functional capacity shown by one of the following: inability to exercise; 6-min walk distance ≤ 300 m; peak Vo2 ≤ 12–14 mL/kg/min
5. History of > 1 hospitalization in past 6 mo
6. Presence of all of the previous features despite "attempts to optimize" therapy, including diuretics and guideline-directed medical therapy, unless poorly tolerated or contraindicated

**BASELINE KNOWLEDGE STATEMENTS**

Readers of this chapter are presumed to be familiar with the following:

- General knowledge of the pathophysiology of acute decompensated heart failure (HF)
- Hemodynamic profile of cardiogenic shock
- Stages and classification of HF with reduced ejection fraction
- Pharmacology of agents commonly used to treat patients with HF, including diuretics, vasodilators, and positive inotropic agents
- Basic pharmacology of drug therapy agents specific to patients with LVAD and HT (e.g., anticoagulants and immunosuppressive agents)

**ADDITIONAL READINGS**

The following free resources have additional background information on this topic:

- 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure; the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-220.

**Table of common laboratory reference values.**
therapy is a reasonable “bridge therapy” (class IIa, level of evidence B). Once patients enter the hospital, the goals of therapy shift toward hemodynamic optimization and preservation of organ function in preparation for HT or LVAD surgery. Patients who are volume overloaded should aggressively be decongested with intravenous loop diuretics, with a goal of normalizing both right- and left-sided filling pressures. A pulmonary artery catheter can be considered to more carefully guide treatment and achieve hemodynamic goals.

Patients with low cardiac output or overt cardiogenic shock should receive inotropic therapy with either milrinone or dobutamine. Restoration of organ perfusion and reversal of shock before surgery are paramount, particularly for LVAD recipients, who have a 30%–50% higher mortality rate when hemodynamically unstable at the time of device implantation (Kirklin 2015). No evidence suggests that one inotropic agent is preferred to the other as a bridge to HT or a durable LVAD; hence, this choice should be guided by the patient response and the potential for toxicity (e.g., tachyphylaxis with dobutamine) or by pharmacokinetic considerations (e.g., renal failure with milrinone). Combination inotropic support with a β-receptor agonist and a phosphodiesterase inhibitor may add efficacy and facilitate lower doses of each agent, which may minimize drug toxicity (Meissner 1992). Dopamine should generally be avoided in these patients, given its extremely unpredictable pharmacokinetic profile (MacGregor 2000) together with its potentially higher mortality rate compared with norepinephrine in patients with cardiogenic shock.

CardSAP 2019 BOOK 1 • Heart Failure

Table 1. Indications and Contraindications for Heart Transplantation and Durable LVAD Therapy

<table>
<thead>
<tr>
<th>Heart Transplantation</th>
<th>Durable LVAD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
<td><strong>Indications</strong></td>
</tr>
<tr>
<td>Cardiogenic shock requiring continuous inotropic support or temporary MCS</td>
<td>NYHA class IV heart failure symptoms</td>
</tr>
<tr>
<td>Persistent NYHA class IV heart failure symptoms refractory to maximal medical therapy (LVEF &lt; 20%; peak oxygen consumption &lt; 12 mL/kg/min)</td>
<td>LVEF &lt; 25%</td>
</tr>
<tr>
<td>Intractable angina not amenable to revascularization</td>
<td>Failure to respond to optimal medical management for at least 45 of the past 60 days</td>
</tr>
<tr>
<td>Intractable arrhythmias</td>
<td>IABP-dependent for 7 days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Contraindications</strong></th>
<th><strong>Contraindications</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic illness with life expectancy &lt; 2 yr (malignancy, AIDS, lupus)</td>
<td>Morbid obesity³</td>
</tr>
<tr>
<td>COPD with FEV₁ &lt; 1 L/min</td>
<td>Small body (BSA &lt; 1.5 m²)³</td>
</tr>
<tr>
<td>Clinically severe cerebrovascular disease</td>
<td>CKD³</td>
</tr>
<tr>
<td>Fixed pulmonary arterial hypertension (e.g., PVR &gt; 3 Wood units)</td>
<td>Mild-moderate hepatic dysfunction³</td>
</tr>
<tr>
<td>Renal dysfunction with eGFR &lt; 30 mL/min/1.73 m²</td>
<td>Malnutrition³</td>
</tr>
<tr>
<td>Age &gt; 70</td>
<td>Sepsis or active infection</td>
</tr>
<tr>
<td>Active infection (not LVAD related)</td>
<td>Severe right HF</td>
</tr>
<tr>
<td>Peptic ulcer disease³</td>
<td>Severe carotid artery disease</td>
</tr>
<tr>
<td>Diabetes with end-organ damage (e.g., neuropathy or poor glycemic control [A1C &gt; 7.5%])³</td>
<td>Severe COPD</td>
</tr>
<tr>
<td>Peripheral vascular disease³</td>
<td>Severe CVA with deficit</td>
</tr>
<tr>
<td>Morbid obesity (BMI &gt; 35 kg/m²)³</td>
<td>Hemodialysis</td>
</tr>
<tr>
<td>Active mental illness or dementia³</td>
<td>Persistent coagulopathy</td>
</tr>
<tr>
<td>Inadequate social support³</td>
<td>Non-cardiac illness with limited life expectancy</td>
</tr>
<tr>
<td>Drug or tobacco use within 6 mo</td>
<td>HF expected to recover without durable LVAD</td>
</tr>
<tr>
<td>HIT within 100 days³</td>
<td></td>
</tr>
</tbody>
</table>

³Denotes a more relative contraindication.

BSA = body surface area; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; CVA = cerebrovascular accident; eGFR = estimated glomerular filtration rate; FEV₁ = fraction of inspired oxygen in 1 s; HF = heart failure; HIT = heparin-induced thrombocytopenia; IABP = intra-aortic balloon pump; LVAD = left ventricular assist device; MCS = mechanical circulatory support; NYHA = New York Heart Association; PAWP = pulmonary artery wedge pressure; PVR = pulmonary vascular resistance.

Information from: Owens AT, Jessup M. Should left ventricular assist device be standard of care for patients with refractory heart failure who are not transplantation candidates? left ventricular assist devices should not be standard of care for transplantation-ineligible patients. Circulation 2012;126:3088-94.
(De Backer 2010). Alternatively, limited evidence suggests that combining a vasopressor agent (e.g., norepinephrine) with an inotrope (e.g., dobutamine) is safer and more effective than epinephrine monotherapy in patients with hypotension and cardiogenic shock (Levy 2011).

In preparing patients with advanced HF for either HT or durable LVAD surgery, the clinical pharmacist should consider de-escalating traditional HF medications. This is particularly true for angiotensin-converting enzyme (ACE) inhibitors, which may be harmful in patients undergoing cardiac surgery. A propensity score-matched cohort study of over 7000 patients undergoing coronary artery bypass grafting surgery found that preoperative ACE inhibitor exposure was associated with a higher risk of death and postoperative renal dysfunction (Miceli 2009). Although the precise mechanism for these harmful effects is unclear, preoperative ACE inhibitor exposure is thought to contribute to vasoplegia, hypotension, and an increase in vasopressor requirements postoperatively. Pharmacists should keep in mind that the goals of care in this situation are optimizing hemodynamics, preserving end-organ function, and minimizing operative risk. Therefore, ACE inhibitor therapy, which provides long-term mortality benefit for those with stage C HF, is not relevant in this clinical scenario.

Management of Anticoagulation and Antiplatelet Therapy

In preparing hospitalized patients for either HT or durable LVAD implantation, the clinical pharmacist should focus on discontinuing long-acting anticoagulants and transitioning to intravenous unfractionated heparin. Outpatients taking a novel oral anticoagulant (e.g., dabigatran or rivaroxaban) should also be transitioned to warfarin. Although reversal agents are now available for these agents, there are no data regarding the safety and efficacy of reversing a novel anticoagulant at the time of LVAD surgery or HT. This is especially true in those listed for HT because donor offers can come at any time, and there are usually only a few hours to prepare the patient for surgery. When a patient with therapeutic anticoagulation requires urgent reversal for HT, current guidelines recommend the use of intravenous vitamin K in conjunction with fresh frozen plasma, prothrombin complex concentrates (PCCs), or recombinant factor VII (Costanzo 2010). These guidelines were published before the approval of 4-factor PCCs in 2013; hence, 4-factor PCCs with vitamin K should be considered the better reversal regimen, given the rapid onset of this new agent, together with the faster preparation time and lower volume load compared with fresh frozen plasma.

Cessation of antiplatelet therapy is a more difficult scenario, specifically in those with recent coronary artery stenting who require dual antiplatelet therapy with aspirin and a P2Y₁₂ receptor antagonist. Preoperative clopidogrel exposure consistently increases the risk of postoperative bleeding in cardiac surgery patients. The risk of pericardial tamponade or reoperation for bleeding is increased when surgery occurs less than 24 hours after discontinuing clopidogrel (Herman 2010). After 1–4 days, clopidogrel preexposure increases the need for transfusion, with the risk diminishing after each additional day. Although ticagrelor’s surgical bleeding profile is similar to that of clopidogrel, prasugrel carries a substantially higher risk and thus should not be used in patients listed for HT or those slated for a durable LVAD (Wiviott 2007). Cangrelor, a non-thienopyridine intravenous antagonist of the P2Y₁₂ receptor, maintained platelet inhibition in the perioperative setting for patients undergoing coronary artery bypass grafting surgery in the BRIDGE trial (Angiolillo 2012). However, this trial was underpowered to evaluate clinical endpoints; hence, the usefulness of cangrelor as a “bridge” therapy in patients awaiting HT or LVAD implantation remains unknown. Preoperative bridging with a glycoprotein IIb/IIIa inhibitor has been described in several case reports and case series, which seem to suggest a high residual risk of stent thrombosis and a high rate of bleeding (Warshauer 2015). As such, glycoprotein IIb/IIIa inhibitors should not be considered for use in perioperative bridging.

In summary, when a pre-HT or pre-LVAD recipient presents with an indication for a P2Y₁₂ receptor antagonist, the clinical pharmacist and the multidisciplinary team must evaluate the overall risk of stent thrombosis and surgical bleeding and decide whether to continue antiplatelet therapy on a case-by-case basis. In addition to clinical factors, the anticipated bridging time must be considered because of the high cost of cangrelor. When the time to surgery may be prolonged (e.g., in those with a common blood type), use of cangrelor may be cost-prohibitive.

EXTRACORPOREAL MEMBRANOUS OXYGENATION

Indications for and Types

Extracorporeal membranous oxygenation (ECMO) is a form of acute temporary MCS capable of fully replacing cardiopulmonary circulation in patients with severe cardiac and/or pulmonary dysfunction. A typical ECMO circuit is composed of a pump, a semipermeable membrane oxygenator, and a heat exchanger. The pump moves blood through the device, with most pumps capable of generating flows sufficient to provide full body circulatory support in an adult patient. The membrane oxygenator is the interface between blood and ambient gases that facilitates the ventilation and oxygenation of the patient’s blood; this can be manipulated by adjusting the oxygen concentration for oxygenation and flow of gas through the system (commonly called “sweep”) to facilitate the ventilation of carbon dioxide. The heat exchanger component of an ECMO circuit, when present, can help facilitate therapeutic hypothermia in the patient receiving ECMO after cardiac arrest and further enable the team to better control the rate of rewarming. Because ECMO has several
potential indications, the configurations of cannulation can vary to best serve a patient’s specific needs. Patients who have cardiac arrest or who may have refractory cardiogenic shock are considered potential candidates for venoarterial (VA) ECMO support because the ECMO is also needed to replace systemic circulation. Patients with preserved cardiac function who only have severe respiratory dysfunction may be eligible for the venovenous configuration of ECMO, in which blood is removed from the venous circulation, oxygenated, and returned to the venous circulation before entering the right side of the heart (Figure 1). Cannulation strategies may be confined to peripheral vessels (peripheral ECMO) or may be cannulated centrally (directly to the vena cava and/or the aorta) when the patient cannot wean from the cardiopulmonary bypass circuit after cardiac surgery. In centrally cannulated ECMO, patients are generally left with an open chest, making this strategy less appropriate for extended duration of support.

In the advanced HF population, ECMO is usually considered a form of MCS that is initiated when the patient’s circulatory status is either not improving or potentially declining despite the use of vasoactive medications with or without intra-aortic balloon pump (IABP) therapy. In addition, ECMO may be implemented in resuscitating a patient in cardiac arrest who may have a reasonable chance of survival. Extracorporeal Life Support Organization (ELSO) registry data analyses reported in January 2018 show current survival to discharge or transfer of adult patients with cardiac dysfunction who undergo extracorporeal life support to be 41%, whereas 29% of those who undergo ECMO cannulation during cardiopulmonary resuscitation (ECPR) survive to hospital discharge or transfer. Depending on the institution’s capabilities, ECMO may be the only available temporary MCS.

In patients with cardiogenic shock unresponsive to medical therapy, VA ECMO is intended to serve as a bridge to recovery of native cardiac function, to a more durable form of MCS, and, in some cases, as a bridge to HT. Because of the underlying critical nature of patients’ conditions requiring VA ECMO, a bridge to durable MCS is generally preferred to a bridge to transplantation because of the risk of poor HT outcomes in such critically ill patients.

**Hemodynamic Consequences of ECMO**

Venoarterial ECMO can dramatically augment the oxygenation and circulation of blood in a patient with cardiogenic shock. Because the pumps used in most modern ECMO circuits are centrifugal continuous flow, diminished (or loss of) pulsatility can be expected. Because the ECMO will account for a significant portion of total cardiac output, native cardiac output may be diminished such that the aortic valve no longer opens. As flow from the ECMO continues throughout each cardiac cycle, diastolic pressure is expected to be higher than in a patient with the same underlying physiology not receiving ECMO support. An important distinction from the percutaneous ventricular assist devices (pVADs) discussed later in the chapter is the fact that VA ECMO does not effectively unload the left ventricle (LV), as evidenced by studies of the pressure-volume loop relationships of different forms of temporary mechanical support devices (Rihal 2015). This may be of clinical significance if the underlying cause of cardiogenic shock is exacerbated by high loading conditions of the LV.

Typically, several positive inotropic and vasopressor medications are actively administered at the time of VA ECMO initiation, but on initiation, the clinical pharmacist should actively monitor and potentially taper vasopressor agents, targeting a minimum mean arterial pressure (MAP) to adequately

---

**Figure 1.** A. Peripheral venoarterial ECMO configuration indicated in refractory cardiogenic shock or cardiopulmonary arrest. B. Peripheral venovenous ECMO configuration indicated in refractory respiratory failure without circulatory compromise.

ECMO = extracorporeal membranous oxygenation.

Reprinted with permission from: Maquet GmbH & Co. KG, Rastatt, Germany.
perfuse vital organs (typically 60–65 mm Hg). Positive inotropic therapy may at times be continued during ECMO support to sustain aortic valve opening and ejection of blood from the LV in order to minimize the risk of intra-cardiac and aortic root thrombus formation. Positive inotropic agents may also facilitate the weaning of ECMO support if the ECMO was initiated amid cardiac arrest in a patient with severe impairment of cardiac contractility (ELSO 2013). The clinical pharmacist should monitor for malignant arrhythmias and consider discontinuing β-adrenergic agonists if electrical instability precludes the weaning of ECMO support. In some cases, patients may be hypertensive after ECMO support is initiated because of elevated systemic vascular resistance. Episodes of hypertension should warrant investigation of appropriate sedation and analgesia to ensure that neither pain nor agitation is driving a hyperadrenergic blood pressure response. If these alternative causes of systemic hypertension have been addressed, afterload reduction should be considered with continuous infusion vasodilating agents (nicardipine, nitroglycerin, nitroprusside) to target a MAP of less than 90 mm Hg, which will improve the flow offered by the ECMO circuit. Negative inotropic anti-hypertensive agents (diltiazem, esmolol, labetalol) should be avoided, if possible, in patients receiving ECMO because of cardiogenic shock, given that these may negatively affect the patient’s ability to be weaned from temporary support.

Complications of ECMO Therapy

The primary complications during ECMO support depend largely on the configuration of ECMO; however, some common complications occur irrespective of cannula placement. One of the most worrisome risks of all forms of MCS are thromboembolic events. Venovenous ECMO poses a risk of embolizing thrombi into the pulmonary arterial circulation. A clot within the VA ECMO circuit can lead to thrombi embolizing to the cerebral and systemic circulation, causing ischemic stroke. These risks are ever-present, even with the most meticulous anticoagulation, which should prompt timely weaning of ECMO once the patient has recovered or is transitioning to a more durable form of MCS. Local thrombotic complications within the ECMO circuit may also contribute to mechanical failure of the device. Detection of thrombosis within the circuit may necessitate exchanging the circuit to avert more catastrophic events and avoid unnecessary transfusion of platelets and other blood products, which may be consumed within a thrombosing ECMO circuit and oxygenator.

Because of the large size of the inflow and outflow intravascular cannulas inserted into major blood vessels, together with any effects of the machine on blood components, bleeding is another potential complication of ECMO therapy. The risk of hemorrhage can be compounded by any existing coagulopathy, which is common in patients with cardiogenic shock and further exacerbated using parenteral anticoagulation and, in some cases, antiplatelet therapy. Careful monitoring of several coagulation components can help minimize bleeding complications, and when bleeding occurs at the site of cannula insertion, prompt surgical intervention may minimize the need to interrupt anticoagulation. Transfusion of blood products, PCCs, and fibrinogen may be considered depending on the clinical situation.

Like in any critically ill patient population, infection remains a constant concern because of the presence of intravascular devices, prolonged nature of mechanical ventilation, and compromise to the immune system that may occur in patients with severe multiorgan dysfunction. In addition, because of the emergency nature of ECMO insertion, which is often conducted at the bedside outside the sterile confines of the operating room, patients may risk inoculation with pathogenic microorganisms present in the health care setting. Because device support can last for several days or weeks, many clinicians may use antibiotics for prophylaxis for a limited duration after insertion of ECMO or for the entire duration of support. Evidence of the benefit-risk of these practices is very limited, and overuse of antimicrobial agents may add a risk of developing multidrug-resistant pathogens, Clostridium difficile superinfection, or other adverse effects of antimicrobial agents, making this practice something that should be used cautiously. Lower respiratory tract and bloodstream infections are the most common types of infections in this population (Haneke 2016; Burket 1999). Authors of a recent systematic review of 11 studies evaluating various prophylactic antibiotic regimens in patients receiving ECMO therapy concluded that no clear evidence supports their use (O’Horo 2016). However, in select patients, including those with open chests after cardiac surgery, extended antimicrobial prophylaxis can be considered.

Anticoagulation During ECMO Support

Unfractionated heparin is the most widely used anticoagulant for patients receiving ECMO support because it has a relatively short half-life, can be readily reversed, and can be titrated easily to achieve a patient-specific level of anticoagulation (ELSO 2014). At the time of cannulation, the ELSO guidelines recommend an initial bolus of 50–100 units/kg of unfractionated heparin, which may not be warranted when the patient is already actively anticoagulated (i.e., during percutaneous coronary intervention or on cardiopulmonary bypass) (ELSO 2014). Much debate remains regarding the most appropriate intensity of anticoagulation of patients receiving ECMO support, as well as the most effective method of monitoring this therapy (ELSO 2014). It is common practice to include several coagulation tests to monitor anticoagulation, which are combined with the patient’s clinical condition (e.g., the presence of bleeding or clinical thrombosis) to guide anticoagulation decision-making. For patients thought to have heparin-induced thrombocytopenia, the direct thrombin inhibitors bivalirudin or argatroban should be considered. Dose selection of the direct thrombin inhibitors should factor in existing coagulopathy and end-organ function because
both bivalirudin and argatroban have had therapeutic levels of anticoagulation at much lower than standard doses in hemodynamically unstable patients requiring ECMO support (Ranucci 2011; Beiderlinden 2007).

Activated clotting time (ACT) and activated partial thromboplastin time (PTT) are the most common coagulation tests used to monitor unfractionated heparin dosing in patients receiving ECMO. Because of the familiarity of aPTT in the ICU setting, many centers consider this the preferred test. However, discordance between the aPTT and the ACT has been described in the neonatal ECMO population (Khaja 2010). Furthermore, a separate analysis showed the aPTT to better correlate with unfractionated heparin dosing than the ACT in patients receiving ECMO (Atallah 2014). Given these findings, it remains unclear whether aPTT or ACT is superior for monitoring anticoagulation in patients receiving ECMO support.

In a recent survey of anticoagulation practices for ECMO centers, the average minimum targeted ACT value was 183 seconds, and the reported average maximum ACT was 210 seconds (Bembea 2013). The ACT specified in the ELSO guidelines is 180–220 seconds (ELSO 2014). Goal therapeutic ranges for aPTT should be made laboratory-specific on the basis of individual laboratory assays, typically targeting standard ranges of 1.5–2.5 times that of baseline. Anti-factor Xa (anti-Xa) assessment may be used at capable centers, and evidence is growing that this may be a safe and reliable strategy for monitoring heparin anticoagulation in these patients. The target anti-Xa range most commonly used is 0.3–0.7 IU/mL (Bembea 2013), though a lower goal of 0.2–0.4 may be considered in patients with a high bleeding risk. A more recent analysis conducted in the pediatric population evaluated the results of a newly implemented anti-Xa monitoring (goal 0.5–0.7 IU/mL) protocol compared with the historic ACT-guided strategy and found that clinical outcomes, including survival, were better with the anti-Xa–guided approach (Niebler 2018). Notable findings included fewer heparin bolus doses reported with the anti-Xa group; less bleeding, including less intracranial bleeding; and fewer blood transfusions required. Important study limitations include that the comparator groups were part of a widespread protocol change, which may also have modified other interventions, ultimately affecting some of these outcomes; however, this experience adds to the growing level of evidence for anti-Xa monitoring of ECMO. Like with aPTT, no strong correlation was observed between anti-Xa and ACT in the previous analysis (Khaja 2010). However, the relationship between aPTT and anti-Xa is also discordant because of the many additional factors that may prolong the aPTT other than unfractionated heparin dosing (Vandiver 2012). Because of the variability between tests, many clinicians manage unfractionated heparin by incorporating several clinical factors in addition to the coagulation tests described.

Thromboelastography (TEG) may also be used for a more complete sense of a patient’s global risk of coagulation and bleeding, with the added value of helping the clinician determine the need for transfusion or antifibrinolytic therapy. Thromboelastography also helps determine the presence of unfractionated heparin anticoagulant effects when a standard TEG R-time is compared with the R-time of a TEG in the presence of heparinase (Salooja 2001). This may help the clinician determine whether the prolongations of aPTT and other coagulation times are attributable to heparin effects or some other coagulopathy associated with organ dysfunction, previous use of oral anticoagulants, or factor deficiency, which may all be encountered in the patient with cardiogenic shock.

Fibrinogen replacement may be indicated if a patient develops a coagulopathy or disseminated intravascular coagulation. If fibrinogen is below critical concentrations (100 mg/dL), cryoprecipitate supplementation may enhance the safety of therapeutic anticoagulation and minimize any risk of spontaneous life-threatening hemorrhage (Levy 2014). Some centers incorporate antithrombin III (AT III) monitoring and supplementation in AT III–deficient patients to avoid heparin resistance and ensure adequate anticoagulation. An analysis of the efficacy of AT III supplementation showed no discernible effect on heparin dosing, though anti-Xa concentrations were greater in those receiving AT III replacement. There was no observed benefit in the need for circuit exchange or overall heparin dosing in this analysis (Byrnes 2014). Within the ELSO guidelines, AT III replacement remains a consideration in acquired AT III deficiency in the presence of excessive heparin dosing (greater than 35 units/kg/hour) and/or an AT III activity level of less than 30% (ELSO 2014).

Impact of ECMO on Pharmacokinetics and Pharmacodynamics

A significant value of clinical pharmacists on the multidisciplinary team is their unique understanding of, appreciation for, and perspective regarding therapeutic drug monitoring. In some cases, this represents monitoring drug concentrations for traditional medications; however, with introduction of an ECMO circuit, there may be additional influences to drug disposition beyond the traditional factors that affect volume of distribution and clearance. During ECMO initiation, there is a significant addition to plasma volume, which immediately affects the volume of distribution (Shekar 2012a; Mehta 2007). This initiation (cannulation) process can add volume to the patient’s systemic circulation using crystalloids, colloids, or blood products as priming solutions for the circuit, which is expected to dilute drug concentrations during ECMO initiation. In addition, many drugs adhere to artificial surfaces and may thus become sequestered within the oxygenator or other components of the ECMO circuit. Of note, the material and design of membrane oxygenators and ECMO circuit components likely vary in the degree of the sequestration effect. This drug loss may be greater during earlier phases of ECMO support, and lipophilic drugs may be more prone to loss within
the circuit. Although hydrophilic drugs are less affected by drug loss, they are still likely to have a greater volume of distribution because of the added plasma volume within the circuit. Drugs that have shown significant loss within ECMO circuits compared with control include fentanyl, midazolam, propofol, heparin, and voriconazole, potentially warranting different management strategies for each to ensure that therapeutic doses are maintained (Shekar 2012a; Shekar 2012b; Mehta 2007). Monitoring of available serum drug concentrations may be warranted, when possible, for medications in which clinical response is difficult to assess otherwise.

**Sedation and Analgesia**

Optimizing sedation and analgesia can be one of the greater challenges in patients receiving ECMO support. Often, patients with refractory respiratory failure may require excessive doses of analgesic and sedative agents. Because oxygen consumption can be increased in agitated patients, poor sedation and persistent agitation may not only cause tissue hypoxia, but may also increase the danger that patients pose to themselves by dislodging ECMO cannulas, endotracheal tubes, nasogastric tubes, and intravascular catheters. Several reports have shown significant sedative or analgesic drug loss within ECMO circuits, including midazolam, propofol, dexmedetomidine, and fentanyl. This phenomenon may warrant greater doses, especially early in ECMO support, because the presence of the ECMO circuit may mimic the drug kinetics found in a multicompartment model (Wagner 2012; Mehta 2007; Mulla 2000). Morphine or hydromorphone may be a useful analgesic alternative to fentanyl in patients with uncontrolled pain receiving ECMO because both these agents are more hydrophilic than fentanyl (Shekar 2012b). Lorazepam may be a less lipophilic benzodiazepine option than midazolam or diazepam but still had some degradation compared with control concentrations in an in vitro model (Mulla 2000). In addition, as might be expected with any multicompartment pharmacokinetic model, a period of drug redistribution may persist after discontinuation, possibly prolonging the sedative effect. Many centers can keep patients awake and, in some cases, non-mechanically ventilated, to encourage mobility, minimizing the risk of mechanical ventilation complications.

**Antibiotic Therapy**

Because of the critical nature and hemodynamic instability of patients receiving ECMO support, suspicion for infection is quite common. Development of new infections while receiving ECMO is a constant concern that should be met with rapid collection of blood, urine, and respiratory tract cultures as well as initiation of empiric broad-spectrum antimicrobial agents on the basis of patient risk factors and local antimicrobial resistance patterns. With any antimicrobial agent selected, loading doses should be given with consideration for the greater volume of distribution present with the ECMO circuit. It is especially important to achieve effective therapeutic concentrations initially in a patient who may be experiencing septic shock. Like with the sedative medications, a component of drug sequestration of antimicrobial agents may be within the circuit that poses the risk of treatment failure because of ineffective drug concentrations (Shekar 2012b). Antimicrobial agents that are quite lipophilic should be avoided, if possible. When therapeutic drug monitoring is feasible (e.g., vancomycin, aminoglycosides), drug concentrations should be monitored often. Most β-lactams are hydrophilic, and cefotaxime, meropenem, and piperacillin/tazobactam are minimally affected by the presence of ECMO; therefore, clinicians can follow conventional dosing for these medications according to the patient’s CrCl (Donadello 2015; Ahsman 2010). For fungal infections, amphotericin B and hydrophilic azole antifungals may be the agents of choice to sustain effective antifungal concentrations, depending on resistance patterns (Watt 2012; Ruiz 2009). Echinocandins have shown inconsistent pharmacokinetics with ECMO, and voriconazole, a lipophilic azole antifungal, has consistently been shown to undergo significant drug loss within the ECMO circuit (Ruiz 2009; Spriet 2009). Finally, for influenza infection, higher doses of the antiviral neuraminidase inhibitor oseltamivir (150 mg twice daily) have been described in patients receiving ECMO, for whom lower drug concentrations were reported than in patients not receiving ECMO (Eyler 2012). This report differed somewhat from a later study describing no difference in oseltamivir concentrations between patients receiving ECMO and patients not receiving ECMO (Mulla 2013). Nonetheless, oseltamivir concentrations at standard doses were considered by both groups of investigators to achieve sufficiently effective concentrations to treat severe influenza infections; therefore, a higher dosing strategy may not be necessary to provide therapeutic concentrations (Mulla 2013; Eyler 2012).

**PERCUTANEOUS VENTRICULAR ASSIST DEVICES**

**Indications for and Types of pVADs**

The main indications for pVAD therapy are either for hemodynamic support during high-risk percutaneous coronary intervention or for use in the setting of refractory cardiogenic shock caused by acute myocardial infarction or severe HF. Currently, two FDA-approved devices may be used in these clinical settings. The first is the Impella series (Abiomed, Danvers, MA), which includes the Impella 2.5, the 5.0, the CP (Cardiac Power), and the RP. The Impella 2.5 is a catheter-mounted microaxial pump mounted on a 9-French catheter shaft, which houses the motor driveline and the purge line system. Insertion is usually done through a femoral approach, and the pump is positioned across the aortic valve into the LV with fluoroscopy (Allender 2017) (Figure 2). Expelling aspirated blood from the LV into the ascending...
aorta, the Impella 2.5 at its maximal rotation speed of 51,000 rpm provides flow of up to 2.5 L/minute. The Impella CP uses the same platform as the 2.5 device but provides additional cardiac support and operates with a mean flow of 3–4 L/minute. The Impella 5.0 device carries a larger motor capable of providing up to 5 L/minute of support and, as such, is inserted into the LV through femoral cutoff or through the axillary artery. Finally, the Impella RP is approved to provide circulatory support to those who develop acute right HF; this pump delivers blood from an inlet area in the inferior vena cava through the cannula to the outlet opening near the tip of the catheter in the pulmonary artery.

Hemodynamic Consequences of pVADs
The Impella devices propel blood from the LV into the ascending aorta, thereby unloading the LV and increasing cardiac output. They reduce myocardial oxygen consumption, improve MAP, and reduce pulmonary capillary wedge pressure (PCWP) (Rihal 2015). The Impella 2.5 provides a greater increase in cardiac output than an IABP but less than the TandemHeart device (Table 2). The more powerful Impella CP and 5.0 devices are similar to the TandemHeart device with respect to MCS. Similar to the TandemHeart, adequate RV function is necessary to maintain LV preload and hemodynamic support during biventricular failure.

During MCS with the TandemHeart, both the LV and the device contribute flow to the aorta simultaneously (thereby working in parallel, or tandem, rather than in series). Redirection of blood from the LA reduces LV preload, LV workload, filling pressures, wall stress, and myocardial oxygen demand (see Table 2) (Rihal 2015). The increase in arterial blood pressure and cardiac output supports systemic perfusion. The aorta is thus perfused and pressured by both the LV and the TandemHeart, with the relative contribution of each varying, depending on LV response to the device. Not infrequently, LV contraction virtually ceases, and perfusion is pump-dependent with a flat MAP curve. Like with the Impella devices, ventricular tachycardia or fibrillation usually (but not always) renders the TandemHeart ineffective because of RV failure.

Anticoagulation During pVAD Support
Successful use of the Impella devices is predicated on effective heparin-based anticoagulation. The manufacturer recommends administering unfractionated heparin through...
a purge solution, which is used to lubricate the motor and maintain a pressure within the device of 300–1100 mm Hg. Historically, the default purge solution is 25,000 units of unfractionated heparin in 500 mL of 20% dextrose solution (50 units/mL), though lower concentrations of unfractionated heparin (e.g., 12.5 or 25 units/mL) can be used if the patient develops supratherapeutic aPTT values.

Recently, the device manufacturer changed the recommended default dextrose concentration to 5%, which is relevant because this reduction in the viscosity of the purge solution will likely increase the flow rate (and thus the unfractionated heparin exposure) by as much as 30%–40%. The device console automatically adjusts the flow rate of the purge to 2–30 mL/hour to maintain purge pressure, which is problematic because such fluctuations can significantly alter the patient’s exposure to unfractionated heparin. Adding to this already complicated scenario is the need to maintain therapeutic anticoagulation (ACT of 160–180 seconds or aPTT of 60–80 seconds), which often necessitates supplemental intravenous unfractionated heparin (Seyfarth 2008).

Simultaneous administration of unfractionated heparin in the purge solution (which is controlled by the console) together with intravenous unfractionated heparin poses a significant hazard for medication error and heparin over- or underdosage. The Patient Case Scenario highlights this problem and offers potential solutions to avoid harm and optimize anticoagulation strategies in these patients.

Similar to the Impella devices, anticoagulation with the TandemHeart is complicated by the need for a heparinized infusate of 1000 mL of normal saline with 90,000 units of unfractionated heparin. This infusate runs at a fixed rate of 10 mL/hour, which, unlike with the Impella devices, will not fluctuate with unfractionated heparin exposure. Of importance, the infusate must be saline because dextrose-containing products can damage the motor and lead to catastrophic failure of the device. Additional unfractionated heparin can be administered intravenously, as needed, to achieve therapeutic anticoagulation (Table 3).

**Table 2. Comparison of Available Temporary Support Devices**

<table>
<thead>
<tr>
<th></th>
<th>IABP</th>
<th>Impella</th>
<th>TandemHeart</th>
<th>VA ECMO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum support</td>
<td>0.5–1 L/min</td>
<td>2.5, 3.5, or 5.0 L/min</td>
<td>Up to 4.1 L/min</td>
<td>≥ 5 L/min</td>
</tr>
<tr>
<td>LV unloading</td>
<td>+</td>
<td>++++,++++</td>
<td>++++</td>
<td>+</td>
</tr>
<tr>
<td>Coronary perfusion</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Bleeding risk</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>++++</td>
</tr>
<tr>
<td>Management complexity</td>
<td>+</td>
<td>++</td>
<td>++++</td>
<td>+++</td>
</tr>
<tr>
<td>Maximum implant timea</td>
<td>Weeks</td>
<td>7 days</td>
<td>14 days</td>
<td>Days to weeks</td>
</tr>
</tbody>
</table>

*aAccording to manufacturer recommendations. VA ECMO = venoarterial extracorporeal membranous oxygenation.

**Table 3. Example Anticoagulation Protocol for the TandemHeart Device**

<table>
<thead>
<tr>
<th>aPTT (seconds)</th>
<th>Instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 55</td>
<td>Continue current infusate (heparin 45,000 units/500 mL saline) at 10 mL/hr, initiate intravenous heparin 2 units/kg/hr</td>
</tr>
<tr>
<td>55–75</td>
<td>Therapeutic – No changes</td>
</tr>
<tr>
<td>76–90</td>
<td>Switch infusate to heparin 25,000 units/500 mL saline at 10 mL/hr, and initiate intravenous heparin at 2 units/kg/hr</td>
</tr>
<tr>
<td>91–110</td>
<td>Switch infusate to heparin 25,000 units/500 mL saline at 10 mL/hr, do not start intravenous heparin</td>
</tr>
<tr>
<td>&gt; 110</td>
<td>Switch infusate to saline (no heparin) at 10 mL/hr</td>
</tr>
</tbody>
</table>


**Complications of pVAD Therapy**

The most commonly reported complications of Impella placement are limb ischemia, vascular injury, and bleeding requiring blood transfusion. Vascular complications common to all transfemoral procedures such as hematoma, pseudoaneurysm, and arterial-venous fistula and retroperitoneal hemorrhage can occur with any mechanical support device. Hemolysis as the result of mechanical erythrocyte shearing has been reported within the first 24 hours of use in 5%–10% of patients, who may respond to repositioning of the device (Lauten 2013). Persistent hemolysis is an indication for device removal. Because the Impella device traverses
**Patient Care Scenario**

A woman (weight 75 kg) is admitted to the ICU with an Impella CP device in place. Her purge solution (25,000 units/500 mL of dextrose 5% in water) is running at 10 mL/hour, or 500 units/hour of heparin. According to the heparin protocol for this hospital, her total hourly heparin dose should be 900 units (75 kg × 12 units/kg) to achieve an aPTT of 60–80 seconds.

**Part 1**

According to this protocol, how much intravenous heparin should the patient receive?

**ANSWER**

The patient should be initiated on an intravenous heparin drip at a rate of 400 units/hour to equal a total hourly dose of 900 units/hour (500 units from the purge plus 400 units intravenously).

**Part 2**

Two hours after starting intravenous heparin, the nurse notices that the Impella controller has reduced the flow rate of the purge solution to 8 mL/hour, or 400 units/hour of heparin. She notifies the physician, who asks the ICU pharmacist for assistance. What is the most appropriate action to take at this time?

**ANSWER**

The pharmacist should recommend increasing the rate of intravenous heparin by 100–500 units/hour so that the patient continues to receive a total hourly dose of 900 units/hour (400 units purge plus 500 units intravenously).

**Part 3**

After 6 hours of support, the first aPTT value is 47 seconds (goal 60–80 seconds). The ICU team asks the pharmacist for assistance with anticoagulation management. What is the most appropriate action at this time?

**ANSWER**

Because the aPTT is subtherapeutic, the patient will require more heparin. This can be accomplished by increasing the intravenous heparin. Remember that the purge flow rate is controlled by the device and cannot be titrated to achieve a therapeutic aPTT. A reasonable solution is to increase the infusion rate for the intravenous heparin by 100 units/hour, and the new total hourly dose will be 1000 units/hour (400 units purge plus 600 units intravenous).

---


---

**DURABLE LVAD THERAPY**

**Indications for and Types of Durable LVAD Pumps**

Current guidelines for managing HF suggest that durable LVAD therapy can be considered to prolong survival in carefully selected patients (see Table 1) with stage D disease (Yancy 2013). These devices can be used as either a bridge-to-transplantation or destination therapy in those who are not candidates for HT. All commercially available LVADs in the United States operate under continuous flow (CF-LVADs); the HeartMate II (Thoratec Corp., Pleasanton, CA) operates through a mechanical-bearing internal impeller (similar to an Archimedes screw) and delivers up to 10 L/minute of cardiac output by axial laminar flow. The HeartWare HVAD (HeartWare International, Framingham, MA) is a smaller pump that is inserted directly into the pericardium; this device uses a water wheel–like impeller to generate full cardiac support by centrifugal flow. The HeartMate III (Thoratec) is a fully magnetically levitated centrifugal pump that is also inserted directly into the pericardium. All devices cannulate the apex of the LV to provide direct mechanical cardiac unloading, and each propels blood forward through an outflow graft anastomosis to the ascending aorta. The HeartMate II and HeartMate III devices provide a snapshot of four device parameters (flow, speed, pulsatility index, and power) on the device counsel, whereas the HeartWare HVAD monitor provides continuous waveform analysis of flow and power (Table 4). Speed is set by the providing clinician with the goal of obtaining optimal flow (which is calculated by the device on the basis of power consumption).
Hemodynamic Consequences of Durable LVADs
Continuous pumping of blood directly from the LV independent of the cardiac cycle results in loss of the normal isovolumic periods. Unlike the other forms of support like the Impella devices, removal of blood from the LV in durable LVADs does not depend on ejection through the aortic valve. As pump flow rate increases, the LV becomes increasingly unloaded, peak LV pressure generation decreases, and myocardial oxygen consumption markedly decreases. At the same time, arterial blood pressure increases such that peak LV pressure and arterial pressure are increasingly dissociated. This direct unloading also results in decreased left atrial and PCWP. Over time, these improvements in blood oxygenation, systemic pressures, and perfusion may reverse the metabolic milieu of end-stage HF and invoke beneficial secondary changes in LV contractility and peripheral resistance.

Management of Hypertension
All CF-LVADs are sensitive to increases in afterload, such that elevations in systemic arterial pressure can impede device function and reduce forward flow (see Table 4). The presence of hypertension also presages a heightened risk of stroke in CF-LVAD recipients (Nassif 2015). Depending on the device speed and the residual native left heart function, these patients will lack pulsatility; thus, blood pressure targets are based on the MAP. Noninvasive blood pressure monitoring is done with a Doppler probe because of the aforementioned loss in pulsatility.

Clinicians facing systemic arterial hypertension (usually defined as a MAP greater than 90 mm Hg) in the early postoperative setting should first assess systemic perfusion and then begin to withdraw inotropic support in patients with adequate mixed venous oxygen saturation (SvO₂) and stable end-organ function. If hypertension persists or these medications cannot be weaned because of low Svo₂ (e.g., less than 65%), a systemic vasodilator should be initiated. If intravenous therapy is needed, nicardipine is often the first drug of choice because of its relatively neutral effects on cardiac inotropy and chronotropy, though sodium nitroprusside can be considered as an alternative. Patients should be transitioned to oral therapy as soon as possible; ACE inhibitors are considered first-line therapy in those with stable renal function.

### Table 4. Device Parameters for CF-LVAD

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal Values</th>
<th>Can Be Elevated by:</th>
<th>Can Be Decreased by:</th>
<th>Pharmacotherapy Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flow</td>
<td>4–6 L/min⁴</td>
<td>Sepsis, Device thrombosis, Aortic insufficiency</td>
<td>RV failure, Dehydration, Hemorrhage, Hypertension, Arrhythmias</td>
<td>Monitor for decreases in flow when titrating β-blockers or diuretics, Titrate afterload-reducing agents to avoid hypertension and optimize flow, Monitor for evidence of blood loss or device thrombosis</td>
</tr>
<tr>
<td>Speed</td>
<td>8800–9800 rpm⁶</td>
<td>None – adjusted by health care team</td>
<td>Dehydration</td>
<td>Sudden drops in speed (i.e., suction event) may indicate dehydration and should prompt assessment of diuretic regimen, fluid status, and potential hemorrhage</td>
</tr>
<tr>
<td>Pulsatility index</td>
<td>4–7 for HeartMate II and 3–5 for HeartMate III⁶</td>
<td>Hypertension</td>
<td>Hypotension, Dehydration, RV failure</td>
<td>Sudden drops in pulsatility index (i.e., suction event) in HeartMate II/III may indicate dehydration and should prompt assessment of diuretic regimen and fluid status</td>
</tr>
<tr>
<td>Power</td>
<td>5–7 W</td>
<td>Device thrombosis, Hypertension</td>
<td>Hypotension, Sepsis</td>
<td>Sustained power elevation should prompt evaluation for device thrombosis</td>
</tr>
</tbody>
</table>

Notes:
⁴Normal value depends on the patient’s BMI.
⁶Typical range for HeartMate II device.
⁵Typical range for HeartWare HVAD.
⁶Typical range for HeartMate III device.
⁶Calculated only by the HeartMate II and HeartMate III devices; when the LV contracts, the increase in ventricular pressure causes an increase in pump flow during cardiac systole. The magnitude of these flow pulses is measured and averaged over 15-s intervals to produce a “pulsatility index” (PI). The magnitude of the PI value is related to the amount of assistance provided by the pump. Higher values indicate more ventricular filling and higher pulsatility (i.e., the pump is providing less support to the LV). Lower values indicate less ventricular filling and lower pulsatility (i.e., the pump is providing greater support and further unloading the ventricle).

and acceptable potassium concentrations (Lampert 2014). Dihydropyridine calcium channel blockers (e.g., amlodipine) are also acceptable, as are β-receptor antagonists (assuming that RV function is adequate). Most CF-LVAD recipients require one or two antihypertensive medications to maintain an optimal MAP (less than 80 mm Hg) (Lampert 2014).

**Management of Ventricular Arrhythmias**

Sustained ventricular arrhythmias can occur in up to 40% of CF-LVAD recipients and are most common in patients with a history of this condition (Raasch 2012). As the LV is completely unloaded, the pathophysiologic sequelae of these arrhythmias may be negligible. Reports exist of patients surviving hours and, in extreme cases, months of ventricular fibrillation. However, the loss of organized contraction from the unsupported RV can lead to hemodynamic destabilization by reducing pump flow secondary to unsatisfactory left-sided volume for ventricular filling (see Table 4). Therefore, treatment decisions regarding ventricular arrhythmias should be made on a case-by-case basis according to the patient’s overall condition. Although asymptomatic arrhythmias may not require intervention, those associated with hypotension, RV failure, or clinical symptoms (e.g., dizziness or palpitations) warrant treatment.

Amiodarone remains the preferred antiarrhythmic agent for CF-LVAD recipients. In addition to the customary monitoring for this agent, clinical pharmacists should be mindful that initiating amiodarone therapy may alter the pharmacodynamic response to warfarin, which is germane because virtually all recipients of durable CF-LVADs require oral anticoagulation (Edwin 2010). For patients who develop intolerance to amiodarone or whose amiodarone therapy fails, lidocaine or mexiletine is an appropriate secondary treatment option. β-Blockers are effective antiarrhythmic medications that should also be initiated, when possible, in CF-LVAD recipients; however, the potential for negative inotropy and RV dysfunction with β-blockers may limit their use (Refaat 2008). Therefore, clinicians should monitor these patients closely for signs of RV failure (see below) whenever initiating or titrating β-blockers.

**Management of RV Failure**

The anatomy and physiology of the RV are quite distinct from those of the LV. The LV has three muscle layers (oblique, circular, and longitudinal), whereas the RV only has two (circumferential and longitudinal) (Sheehan 2008). Furthermore, although the LV exerts powerful torsional and rotational forces, the RV operates using peristaltic contractions (similar to the GI smooth muscles). The RV largely depends on the low hydraulic impedance characteristics of the pulmonary vascular bed and, as such, can achieve comparable output with a myocardial energy cost of about one-fifth that of the LV.

Unanticipated RV failure may occur in up to 40% of recipients of durable CF-LVADs and is associated with significantly worsened survival (Tsiouris 2015). No uniform definition for severe RV failure exists; however, this pathology is commonly described as the need for placement of an RV assist device or use of intravenous inotropes for more than 14 days postoperatively. Many preoperative risk factors for developing RV failure have been identified, including elevations in central venous pressure (CVP), diminished RV stroke work index and RV contractility on echocardiography, and the presence of signs and symptoms suggestive of right HF (Morgan 2013).

Right ventricular failure commonly manifests as a constellation of hypotension, low device flow and low pulsatility indices, and echocardiographic evidence of RV dysfunction (see Table 4). Distinguishing RV failure from other causes of hypotension and low flow (e.g., inadequate device speed or hypovolemia) can be difficult, and continuous pulmonary artery catheter monitoring during pump speed optimization is often necessary to confirm the diagnosis (Figure 3). Although a high PCWP can be managed by increasing the device speed, isolated elevations in CVP (which suggest RV failure) usually require pharmacologic intervention. As mentioned previously, the RV normally exists in a low-pressure environment; thus, even mild elevations in afterload (i.e., high pulmonary vascular resistance [PVR] values) can drastically impair systolic function. This notion was reinforced by recently published data analyses that showed the RV is

![Suspected RV failure (↓ BP, ↓ flow, ↓ SvO\textsubscript{2}, ↑ CVP)](image)

<table>
<thead>
<tr>
<th>PCWP also elevated?</th>
<th>Yes</th>
<th>Increase speed, ± diuretic therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td></td>
<td>Consider inodilator (e.g., dobutamine)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PVR &gt; 3 Wood units OR TPG &gt; 12 mm Hg?</th>
<th>Yes</th>
<th>Consider iNO, inhaled epoprostenol, inhaled milrinone, inhaled iloprost</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 3.** Flow chart for pharmacologic management of right-ventricular (RV) failure.

BP = blood pressure; CVP = central venous pressure; Sv\textsubscript{O}\textsubscript{2} = mixed venous oxygen saturation; PCWP = pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; TPG = transpulmonary gradient; iNO = inhaled nitric oxide.
more sensitive to even small increases in afterload pressure early after CF-LVAD implantation (Houston 2016). Therefore, the choice of agent for pharmacologic support of the failing RV hinges on the patient's PVR value (Figure 4). For RV failure with normal PVR values, traditional inotropic therapy (i.e., dobutamine or milrinone) should be sufficient to improve contractility and RV output. Conversely, if the PVR is elevated (greater than 250 dynes/second/cm^5 or 3 Wood units) or the patient has other evidence of a high RV afterload (e.g., a transpulmonary gradient greater than 12 mm Hg [mPAP-PCWP]), a selective pulmonary artery vasodilator is the preferred initial pharmacologic agent. A complete review of these agents is beyond the scope of this chapter; however, Table 5 includes a summary description of the medications commonly used in the ICU for acute RV failure. Inhaled nitric oxide is historically the most common treatment; however, this therapy is significantly limited because of its high cost. Inhaled epoprostenol is significantly less expensive than inhaled nitric oxide but is cumbersome to administer and can increase bleeding risk through inhibition of platelet aggregation (Groves 2014). Recent pilot data analyses suggest that inhaled milrinone can also be used for acute RV failure after CF-LVAD implantation; however, absorption from the pulmonary circulation produces therapeutic plasma milrinone concentrations; hence, patients receiving this modality may be at risk of hypotension and cardiac arrhythmias (Haglund 2015). For severe, refractory postoperative pulmonary arterial hypertension, combining inhaled pulmonary vasodilators with complimentary pharmacology (e.g., epoprostenol plus milrinone or inhaled nitric oxide plus iloprost) can be considered as salvage therapy (Antoniou 2013; Haraldsson 2001). If pharmacology does not reverse RV failure, mechanical right heart support should be initiated. However, the need for an RV assist device after CF-LVAD implantation is associated with a high postoperative mortality (Morgan 2013). If patients with an elevated PVR respond to inhaled pulmonary vasodilators and recover from RV failure, transition to an oral pulmonary vasodilator (e.g., sildenafil) can be considered.

### Thromboprophylaxis During LVAD Support

All commercially available durable CF-LVADs carry a risk of thrombosis, which can include clotting within the device itself (i.e., pump thrombus) as well as ischemic stroke caused by device-related emboli. Lifelong combination therapy with warfarin-based anticoagulation and antiplatelet agents is required to mitigate these complications. No randomized data exist comparing anticoagulation regimens in CF-LVAD recipients; as such, significant heterogeneity exists within the field, and practice is often guided by local center experience (Jennings 2016). For both the HeartMate II device and the HeartWare HVAD, intravenous unfractionated heparin should be initiated as soon as surgical hemostasis has been achieved. Both device manufacturers recommend targeting a lower aPTT for the first 24–48 hours (e.g., 45–50 seconds), with the eventual goal of titrating it toward 55–65 seconds (Maltais 2017). Aspirin should also be initiated by postoperative day 2 at a dose of 81 mg daily for the HeartMate II/III and a dose of 162–325 mg daily for the HeartWare HVAD. For the HeartMate II device, some centers still use dual antiplatelet therapy with aspirin and dipyridamole, whereas other centers (particularly in Europe) omit antiplatelet agents entirely (Jennings 2016).
When transitioning from unfractionated heparin to warfarin, the clinical pharmacist should assist with dosing, particularly when major drug-drug interactions are present. If the patient was taking warfarin before CF-LVAD implantation, historical requirements can be used as a basis for postoperative dosing (Jennings 2012). Warfarin genotype data, if available, can also help in selecting an appropriate initial dosing regimen (Jennings 2016). Of note, the pharmacist should ensure that unfractionated heparin is overlapped until at least five doses of warfarin have been administered and until the INR is therapeutic for at least two readings taken 24 hours apart (Colombo 2016).

The HeartMate II, HeartMate III, and HeartWare HVAD manufacturers advocate an INR target of 2–3; however, many centers use narrower ranges (e.g., 2–2.5 or 2.5–3) (Jennings 2016). Although no randomized data analyses have compared one INR target range with another, use of narrower targets is usually associated with lower time within the therapeutic range and poorer anticoagulation quality (Kuyumjian 2016). In light of this, a standard initial INR of 2–3 is recommended for all recipients of durable CF-LVADs. This recommendation is further supported by a recent analysis of over 10,000 INR values in 249 HeartMate II recipients, which found that the optimal INR was 2.6 on the basis of weighted mortality of thrombotic and bleeding events, with low rates of adverse events at INR values of 2.0–3.2 (Nassif 2016).

The HeartMate III device was designed with specific features to enhance hemocompatibility and reduce the risk of thrombosis; these include a fully magnetically levitated rotor, wide blood flow passages, and an intrinsic pulse designed to avert stasis within the pump. In the 2-year results from the pivotal MOMENTUM 3 randomized trial, suspected events of pump thrombosis occurred in 2 patients (1.1%) in the centrifugal-flow pump group compared with 27 patients (15.7%) who had 33 such events in the axial-flow pump group (HR 0.06; 95% CI, 0.01–0.26; p<0.001) (Mehra 2018). Given this more forgiving thrombotic profile, pilot data have already been published exploring lower-intensity anticoagulation. MAGENTUM 1 is a prospective, single-arm pilot study of 15 HeartMate III recipients who received standard warfarin anticoagulation (INR 2.0–3.0) and aspirin for 6 weeks postimplantation, followed by a lower INR target of 1.5–1.9 for 6 months (Netuka 2018). The primary end point of survival free from pump thrombosis, disabling stroke, or major bleeding during follow-up was met in 14 of 15 patients (one patient developed GI bleeding). Although these data are preliminary, they support the feasibility of reduced-intensity anticoagulation for the HeartMate III and pave the way for additional investigation of this promising strategy.

Data analyses exploring the use of non-warfarin-based anticoagulation are limited to one small report from a single-center,
randomized, open-label study of 16 HeartWare HVAD recipients in Vienna (Andreas 2017). Patients with normal or impaired renal function (GFR greater than 80 mL/minute/1.73 m² or between 80 and 30 mL/minute) received phenprocoumon or dabigatran at a dose of 110 or 75 mg twice daily. The study was terminated prematurely when four of the eight HeartWare HVAD recipients had a thromboembolic event. Although disappointing, these results must be viewed in the context of the study limitations, most notably the small sample size and the nonstandardized dosing of dabigatran, which likely produced markedly insufficient drug concentrations to protect against device thrombosis. Nonetheless, pending the publication of additional research, warfarin should remain the only anticoagulant used for thromboprophylaxis in all the commercially available CF-LVADs.

Infectious Complications of Durable LVAD Therapy

Infection is a major complication associated with LVAD therapy, with reported rates of 25%–80% (Nienaber 2013). The clinical spectrum of infection in CF-LVAD recipients includes infections related to the device (e.g., the percutaneous driveline) as well as non–LVAD-related infections (e.g., pneumonia, bacteremia). Chronic infection of the driveline is the most common infection site (Nienaber 2013). Some CF-LVAD recipients may develop severe infections, including bacteremia and sepsis. When patients present with severe infection and critical illness, clinical pharmacists must be familiar with the epidemiology of CF-LVAD infections as well as the potential for altered pharmacokinetics of antimicrobial therapy in durable device recipients.

Several studies have shown that the continuum of pathogens associated with LVAD-related infection encompasses gram-positive and gram-negative bacteria as well as fungal species. Methicillin-sensitive Staphylococcus aureus, coagulase-negative staphylococci, methicillin-resistant S. aureus (MRSA), Enterococcus sp., Pseudomonas aeruginosa, Klebsiella sp., Escherichia coli, Stenotrophomonas sp., Serratia sp., Candida sp., Propionibacterium sp., diphtheroids, and Corynebacterium sp. have all been identified in these patients (Nienaber 2013). As such, pharmacists caring for CF-LVAD recipients with severe infections should initiate broad-spectrum antimicrobial therapy, including agents that cover resistant bacteria (e.g., methicillin-resistant gram-positive cocci and Pseudomonas sp.) and Candida sp. (Kusne 2017). For patients with more benign infections (e.g., local driveline site), delaying therapy until the pathogen is identified is an acceptable approach (Kusne 2017). Specific agents (both antimicrobial and antifungal) should be chosen together with infectious disease physicians and should incorporate local antibiogram data. However, the optimal treatment duration for CF-LVAD–related infections remains undefined. Recent guidelines advocate short courses for patients with uncomplicated infections (e.g., 2 weeks), whereas patients with more severe infections such as bacteremia or pump pocket infection may require treatment for 6–8 weeks or longer, depending on the infection (Kusne 2017).

Limited data analyses have suggested that CF-LVAD recipients have a larger volume of distribution and a lower-than-anticipated drug clearance compared with non-LVAD recipients, even in the face of apparent euvoolemia and normal hemodynamics (Jennings 2014). Clinical pharmacists must therefore be vigilant with monitoring for both clinical efficacy and toxicity associated with antimicrobial therapy and must implement therapeutic drug monitoring whenever possible.

Recently published guidelines have provided recommendations for antimicrobial prophylaxis for the first time. These recommendations are summarized in Box 2.

Bleeding Complications of Durable LVAD Therapy

Gastrointestinal bleeding, often originating from arteriovenous malformations within the small intestine and colon, affects over 15% of patients receiving durable LVAD support (Goldstein 2015). Recent evidence suggests that the sustained elevations in serum thrombin concentrations during mechanical support generate an excess of angiopoietin-2, which appears to drive the growth of these arteriovenous malformations (Tabit 2016). Compounding these anatomic lesions is the depletion of high-molecular-weight von Willebrand multimers from LVAD-induced sheer stress, which produces a physiologic state of hypocoagulability (Bartoli 2015). Although these anatomic and physiologic derangements can lead to persistent and recurrent mucosal bleeding, they are sometimes types of life-threatening hemorrhage. Initial management of GI bleeding is predominantly nonpharmacologic (i.e., endoscopic intervention) (Goldstein 2015). Several drug therapies have had proven benefit in small case series

Box 2. Summary of Recommendations for Antimicrobial Prophylaxis During LVAD Implant

- Regimen should target Staphylococcus sp.
- Regimen should cover MRSA in colonized patients
- Routine broad-spectrum gram-negative prophylaxis is not recommended unless guided by local epidemiologic data
- Rifampin prophylaxis is not recommended because of drug-drug interactions
- Routine antifungal prophylaxis is not recommended
- Duration of antimicrobial prophylaxis should not exceed 48 hr
- Duration of prophylaxis should not be based on the presence of chest tubes or drains

and case reports, including octreotide, ACE inhibitors, and thalidomide. A comprehensive review of the evidence for each of these agents was recently published (Sieg 2017). Although the supporting evidence for each of these modalities is limited, the authors of this review proposed a treatment algorithm that was based on their expert opinion (Figure 5).

Finally, although the HeartMate III was clearly superior in reducing pump thrombosis, rates of GI hemorrhage were similar between this device and the HeartMate II (Mehra 2018). These findings highlight the need for continued advances in pump technology to combat additional adverse events beyond device thrombosis.

Because of the innate thrombotic nature of CF-LVADs, bleeding necessitating anticoagulation reversal is a particularly precarious clinical scenario with the potential for catastrophic complications. As such, anticoagulation reversal should be reserved for patients with a potentially life-threatening hemorrhage. Limited data analyses suggest that common modalities, including 3- and 4-factor PCCs, vitamin K, and fresh frozen plasma, are safe to reverse the effects of warfarin (Chen 2015; Jennings 2014). In accordance with published guidelines for anticoagulation in non-LVAD recipients, a regimen of a 4-factor PCCs and intravenous vitamin K is the preferred warfarin reversal strategy in CF-LVAD recipients (Guyatt 2012) with a life-threatening bleed. Because of the high risk of thromboembolism associated with recombinant factor VIIa in CF-LVAD recipients, this agent should be avoided, if possible, for reversal of warfarin in the setting of acute hemorrhage (Jennings 2014). For patients with non–life-threatening bleeding or for those who require a nonemergency surgical procedure, anticoagulation reversal is not recommended, given the potential risk of thrombosis.

Should the clinical pharmacist be forced to reverse anticoagulation, device settings (see Table 4), hemodynamic parameters (e.g., blood pressure and cardiac output), and laboratory measurements of hemolysis (e.g., serum lactate dehydrogenase and plasma free hemoglobin) should all be diligently monitored for signs of pump thrombosis (see discussion in the text that follows in thrombotic complications). Recent literature suggests that acute hemorrhage and the ensuing interruption in anticoagulation is a risk factor for subsequent thrombotic complications (Stulak 2014). Therefore, once hemostasis has been achieved and the patient is clinically stable, anticoagulation should usually be reinitiated carefully with unfractionated heparin. Warfarin should only be reinitiated after the patient has remained free from recurrent bleeding on therapeutic unfractionated heparin for 24–48 hours.

![Figure 5. Treatment algorithm for GI bleeding in CF-LVAD recipients.](image)

ACEi = ACE inhibitor; ARB = angiotensin receptor blocker; GIB = gastrointestinal bleed.
HEART TRANSPLANTATION

Heart transplantation remains the gold standard surgical treatment for patients with advanced HF. One-year survival after HT is greater than 90%, and median survival was recently reported as greater than 10 years, making this a more definitive solution to treating advanced HF in the appropriately selected population (Lund 2017). Because of the limited donor availability relative to prospective recipients, candidates are screened to ensure they are most qualified (see Table 1). As mentioned previously, the care team’s goals include optimizing the patient’s overall condition through positive inotropic medications, nutrition support, and MCS, if needed. Transplantation in hemodynamically unstable patients or patients with multiorgan dysfunction or severe nutritional deficiencies would cause poor outcomes and hence is avoided at most centers. According to the available statistics published by the International Society for Heart and Lung Transplantation (ISHLT), there is a growing trend of providing MCS to patients with advanced HF before HT, which was reported in less than 20% of heart recipients in 2000 but increased to about 50% in 2013 (Lund 2017). There remains an evolving relationship and respective place in therapy for MCS and HT in advanced HF.

Immunosuppression and Rejection

Immunosuppression is given to HT recipients beginning intraoperatively to prevent acute cellular- and antibody-mediated (humoral) rejection at all phases after HT. High doses of intravenous corticosteroids (usually 500–1000 mg of methylprednisolone) are given intraoperatively before the vascular clamps are removed and the new graft is perfused. Many centers (about 50% worldwide) give an additional induction agent in combination with intravenous steroids. According to most recent registry data, the most common choice of agent is an interleukin-2 receptor antagonist (basiliximab), which is given to 30% of HT recipients. Around 20% of HT recipients receive induction with antithymocyte globulin at the time of transplantation (Lund 2017). Use of these induction agents remains controversial because there is no clear benefit on long-term survival reported in the registry data associated with their use. However, their use may be considered in patients determined to be at a higher risk of rejection, particularly antithymocyte globulin in patients who have elevated panel-reactive antibodies (Lund 2017; Costanzo 2010). Although no randomized trials have compared their use, an analysis of the ISHLT registry showed potentially improved survival of antithymocyte globulin induction over basiliximab induction (Ansari 2015). After surgery, corticosteroids are tapered slowly as calcineurin inhibitors and antiproliferative immunosuppression agents (mycophenolate mofetil, sirolimus or azathioprine) are initiated within the first few postoperative days to weeks. Tacrolimus is generally regarded as the preferred calcineurin inhibitor in HT, and target troughs early posttransplantation are 10–15 ng/mL (Lund 2017; Costanzo 2010). Adjustments

Thrombotic Complications of Durable LVAD Support

A comprehensive overview of the pathophysiology of device-related thrombosis is beyond the scope of this chapter and has recently been described elsewhere (de Biasi 2015). In brief, because of the inherent lack of hemocompatibility of the blood-contacting surfaces within the pump, thrombus formation begins when activated platelets and the titanium alloy interface through adhesion proteins (e.g., von Willebrand factor). As activated platelets continue to aggregate, local concentrations of tissue factor spike and form complexes with factor VIIa, hence stimulating the extrinsic pathway. Concurrently, contact proteins (e.g., high-molecular-weight kininogen) also adhere to the metal surface of the device and promote further generation of thrombin through the intrinsic pathway. The net result of these converging coagulation cascades is the formation of a stabilized clot within the device, which exponentially increases shear stress on erythrocytes. The ensuing hemolysis perpetuates this vicious cycle through carbon monoxide release, which is itself a procoagulant molecule.

As the clot expands, either within the pump motor itself or in the cannula, device function eventually becomes compromised. Patients usually then begin to manifest clinical signs of device thrombosis, such as overt HF symptoms, cardiogenic shock and organ malperfusion, hemolysis (e.g., elevations in serum lactate dehydrogenase and hematuria), and derangements in device parameters (see Table 4). All the commercially available devices are radiopaque, and as such, the diagnosis of device thrombosis is based on clinical suspicion and through the exclusion of alternative pathologies (Goldstein 2013). Pump-speed change testing, or a ramp test, can be a useful ancillary diagnostic modality in the HeartMate II patient population (Estep 2014). Pharmacotherapy for acute device thrombosis can include unfractionated heparin, direct thrombin inhibitors (e.g., argatroban), glycoprotein IIb/IIIa inhibitors, and thrombolytic agents. Evidence to support these therapies is limited to case reports and case series; the aggregate experience of these small series suggests that the failure rate for medical therapy is unacceptably high (Jennings 2015). One notable exception seems to be the use of thrombolysis with the HeartWare HVAD, but only when this therapy is guided by log file analysis (Jorde 2015). Log files of power readings stored in the device may identify signals of thrombosis and allow for early intervention before thrombi become too extensive to be treated pharmacologically. Outside this specific scenario, surgical therapy with device exchange should be pursued first line for suspected device thrombosis. Medical therapy should be reserved as salvage treatment for those who are not candidates for surgery, keeping in mind that outcomes in this scenario are poor and patients are at risk of hemorrhagic complications.
to immunosuppression are based on the toxicities of medications, graft function, and pathologic evidence of rejection from surveillance biopsy assessment.

Rejection diagnosis and treatment is quite complex, and management strategies remain largely controversial. Hence, this chapter will briefly introduce rejection after HT. Rejection is generally diagnosed when patients have evidence of graft dysfunction, or it may be diagnosed by routine surveillance biopsies early after HT. Rejection is classified as cellular mediated or antibody mediated, with cellular rejection more common. The diagnosis of rejection largely depends on a histopathologic assessment of an endomyocardial tissue specimen obtained from a biopsy, where several techniques and staining are used to identify the presence of lymphocytes, macrophages, complement deposition, and evidence of myocyte damage. The type of rejection determines the appropriate drug therapies. If rejection is strongly suspected in a patient with hemodynamic compromise, high-dose intravenous corticosteroids (500–1000 mg of methylprednisolone) are given before analysis of biopsy specimens (Costanzo 2010). In severe hemodynamic instability in the presence of rejection, antithymocyte globulin should be considered because it has cytolytic effects for all lymphocytes, including T cells and B cells. According to surveillance biopsy data analyses, the presence of donor-specific antibodies and the patient’s known history of antibody-mediated rejection, plasmapheresis, and other drug therapies including rituximab, intravenous immunoglobulin, proteasome inhibitors, eculizumab, or alemtuzumab may be considered for antibody-mediated rejection (Table 6).

### Hemodynamic Support and Arrhythmia Management After HT

After HT, patients are expected to receive vasoactive infusions to support cardiac function and increase systemic vascular resistance, if necessary, as they are transitioned from cardiopulmonary bypass and the transplanted heart begins to assume its role in providing total cardiac output. Patient hemodynamics can be quite labile during the early postoperative period and may require frequent assessment and adjustment of vasoactive infusions. In many cases, patients in the immediate postoperative period have signs of systemic inflammatory response syndrome and may require vasopressors to maintain a MAP greater than 60 mm Hg. Cardiac function in HT recipients can vary in the early postoperative stage, with some patients immediately achieving optimal cardiac output and others requiring time to recover. Causes of decreased cardiac output during this time can include rejection or primary graft dysfunction. Rejection at this time point is classified as hyperacute because it occurs within minutes to hours of graft reperfusion (Costanzo 2010). Primary graft dysfunction is characterized by cardiac dysfunction in the absence of immunologic-mediated injury. Inotropic support should be slowly tapered after HT, with careful attention given to changes in the patient’s heart rate and cardiac output. Early graft dysfunction may be so severe that it necessitates temporary MCS until recovery or treatment of rejection, if present, can be implemented.

Inhaled vasodilators including inhaled nitric oxide or prostanoclylins may be used to reduce RV afterload or manage RV dysfunction after HT, which can occur in recipients with elevated PVR (Costanzo 2010). Typically, these agents are given with inotropes, which are potentially transitioned to oral phosphodiesterase type 5 inhibitors (e.g., sildenafil), if needed.

Heart transplant recipients may be prone to bradycardias and sinus node dysfunction because the newly implanted heart has been denervated at the time of transplantation. This denervation results in autonomic deregulation of intrinsic heart rate, and instead, the natural heart rate is influenced by intrinsic pacemaker potential of cardiac myocytes and circulating catecholamines. Sympathetic denervation impairs the ability to generate an increased heart rate response to

### Table 6. Summary of Drug Therapies for Antibody-Mediated Rejection

<table>
<thead>
<tr>
<th>Drug Therapy</th>
<th>Proposed Mechanism of Action</th>
<th>Relative Drug Expense</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticosteroids</td>
<td>Up-regulation of anti-inflammatory gene expression</td>
<td>$</td>
</tr>
<tr>
<td>Intravenous immunoglobulin</td>
<td>Blocks Fc-γ receptor; inhibits complement; down-regulates B-cell receptor; neutralizes circulating antibodies and cytokines</td>
<td>$$$$</td>
</tr>
<tr>
<td>Antithymocyte globulin</td>
<td>Depletes T lymphocytes and some B lymphocytes</td>
<td>$$$</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Monoclonal antibodies against CD20, depletes B cells</td>
<td>$</td>
</tr>
<tr>
<td>Bortezomib/carfilzomib</td>
<td>26S proteasome inhibitor on plasma cells, depletes B cells and plasma cells</td>
<td>$</td>
</tr>
<tr>
<td>Eculizumab</td>
<td>Terminal complement inhibitor</td>
<td>$$$$$</td>
</tr>
</tbody>
</table>

exercise or other stressors affecting exercise tolerance, and parasympathetic denervation may eventually lead to a higher resting heart rate. During early posttransplantation, bradyarrhythmias and relative chronotropic incompetence pose a greater concern to the ICU treatment of HT recipients and usually resolve within days to weeks after transplantation. The target heart rate immediately after transplantation is usually 90–110 beats/minute; however, in select patients, a slower heart rate may be safe as long as the rhythm is regular and cardiac output is sufficient (Costanzo 2010). Inotropic agents provide chronotropic support; then, in select patients, backup pacing may be necessary to maintain a heart rate sufficient to support cardiac output. Isoproterenol is usually regarded as the intravenous drug of choice to manage chronotropic incompetence. Nevertheless, recent increases in isoproterenol acquisition costs have led clinicians to consider alternatives, including dobutamine, dopamine, and epinephrine, depending on other patient-specific factors (e.g., blood pressure, cardiac output). All chronotropic agents can cause tachyarrhythmias, including ventricular tachycardia, making ongoing telemetry monitoring critical to ensuring the safety of these agents. Oral drug therapies including terbutaline and theophylline have been used with anecdotal success in transitioning patients from intravenous chronotropic support (Costanzo 2010; Coons 2004; Bertolet 1996; Redmond 1993; Ellenbogen 1988). Tachyarrhythmias may often be managed simply by reducing the use of chronotropic infusions, when present; however, occasionally, nonpharmacologic cardioversion of malignant arrhythmias may be necessary. Amiodarone has been used in patients after HT for both atrial and ventricular arrhythmias; nonetheless, amiodarone use should always be considered temporary because its long-term toxic effects on the transplanted heart and other organs are undesirable (Costanzo 2010). Digoxin is generally considered ineffective as a rate-controlling agent after HT, and agents with negative inotropic properties should be avoided in the early postoperative period after HT (Costanzo 2010; Stecker 2005). Attention should be paid to relevant drug-drug interactions if amiodarone is used in the presence of calcineurin inhibitors because amiodarone increases drug exposure (Page 2005).

Antimicrobial Prophylaxis and Infectious Complications

Because of the immunosuppression required to prevent rejection in patients after HT, clinical pharmacists should be particularly aware of any infectious complications, especially in the postoperative ICU phase. Patients are routinely given standard antibacterial prophylaxis around the time of surgery, which should include coverage of skin flora (e.g., MRSA). Because many patients with ventricular assist devices may receive transplants with chronic device infections, an appropriate treatment course tailored to the microbiologic culture data posttransplantation after device removal should be considered (Anesi 2018; Costanza 2010). Opportunistic infections are uncommon in the first month after transplantation; however, the guidelines indicate initiation of Pneumocystis jiroveci pneumonia (PJP), cytomegalovirus (CMV) and mucocutaneous Candida prophylaxis within the first few days postoperatively (Costanzo 2010; Fishman 2007). Sulfamethoxazole/trimethoprim is considered the gold standard for PJP prophylaxis in patients after HT. Alternatives can be considered for patients with sulfa allergies, hyperkalemia, or other potential adverse effects related to sulfamethoxazole/trimethoprim. Antiviral prophylaxis should be based on donor and recipient CMV immunoglobulin G (IgG) matching to determine the risk level and need for dual CMV plus herpes simplex virus prophylaxis compared with herpes simplex virus–only prophylaxis. Donor-positive CMV IgG and recipient-negative CMV IgG is considered high risk, any recipient-positive CMV IgG is considered intermediate risk, and both donor- and recipient-negative CMV IgG is considered low risk. Prophylaxis with valganciclovir is generally recommended for both intermediate- and high-risk patients, whereas acyclovir or valacyclovir prophylaxis is appropriate for low-risk patients (Costanzo 2010). Some centers follow preemptive therapy with weekly monitoring of CMV antigen titer instead of routine prophylaxis in intermediate-risk patients, in which case patients should receive acyclovir-based prophylaxis to prevent other types of herpes viral infections. Systemic antifungal prophylaxis is not currently a standard practice for all HT recipients; nevertheless, an analysis showed that those who, before transplantation, are receiving ECMO, receiving renal replacement therapy, or having Aspergillus airway colonization may be at a greater risk of invasive fungal infections after HT (Tissot 2014). Current standard prophylaxis for oropharyngeal candidiasis is nystatin 400,000–600,000 units four times daily or oral clotrimazole lozenges beginning after the patient is extubated postoperatively (Costanzo 2010).

CONCLUSIONS AND FUTURE DIRECTIONS

Mechanical circulatory support devices and HT have greatly improved the survival of select patients with advanced HF. The clinical pharmacist plays an integral role in optimizing pharmacotherapy associated with these treatments. Future advances in device technology are focused on removing the necessary driveline through alternative internalized power sources, improving biocompatibility with the blood coagulation system, and addressing the common problem of RV failure through more effective biventricular support or improved total artificial heart technology. Future advances in HT are focused on widening organ availability, improving the heart allocation system, enhancing crossmatching techniques to allow for lower-intensity immunosuppression, and developing drug therapies that selectively prevent rejection without increasing...
Practice Points for Treating the ECMO Recipient

In determining the optimal treatment for patients receiving ECMO, the clinical pharmacist should monitor and optimize the following aspects of therapy:

- The cause of hemodynamic and/or respiratory decompensation leading to the need for ECMO should be determined to ensure the effective treatment of underlying causes (e.g., arrhythmia, pulmonary embolism, progressive systolic HF, acute coronary syndrome, pneumonia).

- Anticoagulation should be evaluated on the basis of laboratory and clinical parameters and adjusted to minimize the risk of thromboembolic complications on ECMO support. Bleeding should be carefully monitored because these patients remain at a high risk of coagulopathy and major bleeding throughout the support.

- Vasoactive drips may be adjusted to target a MAP of 60–90 mm Hg. Inotropes may be used to enhance pulsatility in patients receiving VA ECMO to minimize the risk of intracardiac thrombus formation and facilitate the weaning from MCS.

- Patients receiving ECMO should be monitored carefully for infection because of several risk factors. Prophylactic antimicrobial strategies may be considered, and in patients with signs/symptoms of infection, broad-spectrum antibacterial and antifungal therapy should be initiated and adjusted on the basis of available sensitivity results.

- Analgesia and sedation therapies should be tailored to patient-specific needs with the goals of achieving ventilation/perfusion goals, maintaining the patient’s safety, and minimizing the use of long-acting sedating agents or agents that could negatively affect the patient’s hemodynamics.

the undesirable risks of infection and malignancy that remain common in HT recipients today. As the field moves forward, clinical pharmacists’ continued contributions to this patient population will ensure the best outcomes.

REFERENCES


Mehra MR, Domanski MJ. Should left ventricular assist device should be standard of care for patients with refractory heart failure who are not transplantation candidates?: left ventricular assist devices should be considered standard of care for patients with refractory heart failure who are not transplantation candidates. Circulation 2012;126:3081-7.


Nassif ME, LaRue SJ, Raymer DS, et al. Relationship between anticoagulation intensity and thrombotic or bleeding outcomes among outpatients with continuous-flow left ventricular assist devices. Circ Heart Fail 2016 May 9.


Self-Assessment Questions

1. A 64-year-old man is readmitted for acute decompensation of his longstanding heart failure (HF) with reduced ejection fraction. He also has atrial fibrillation, hypertension, hyperlipidemia, and ischemic coronary disease. Because of his persistently severe symptoms and frequent readmissions, he is worked up for heart transplantation (HT) and successfully listed. Given his disease severity, his listing status will ensure that his surgery will occur in the next 4–6 weeks. His active medication profile includes aspirin 81 mg daily, atorvastatin 80 mg daily, lisinopril 10 mg daily, furosemide 80 mg twice daily, and spironolactone 25 mg daily. You are the clinical pharmacist caring for this patient on the cardiology stepdown ward. Which one of the following would be most appropriate to discontinue in anticipation of this patient's impending transplant surgery?
   A. Aspirin
   B. Atorvastatin
   C. Lisinopril
   D. Furosemide

2. A 46-year-old man presents with an acute myocardial infarction and cardiogenic shock. He receives percutaneous coronary intervention with drug-eluting stent placement to the left anterior descending and right coronary arteries. An Impella 2.5 device is used for hemodynamic support. However, the patient remains dependent on percutaneous ventricular assist device (pVAD) and inotrope support. He is subsequently listed for HT as status 1a and will remain in the ICU until he receives an organ. He has a relatively common blood type, so he is expected to receive a transplant within 1–2 weeks at status 1a. His medication regimen includes ticagrelor and aspirin. Which one of the following, in addition to discontinuing ticagrelor, would be best to recommend for this patient?
   A. Initiate epifibatide therapy.
   B. Initiate clopidogrel therapy.
   C. Continue aspirin monotherapy.
   D. Initiate cangrelor therapy.

3. A 67-year-old woman (weight 63 kg) is admitted with an acute anterior ST-segment elevation myocardial infarction (STEMI) with severe refractory cardiogenic shock requiring Impella CP support. She arrives in the ICU with a purge solution containing 25,000 units of heparin in a 500-mL solution of 5% dextrose. The purge is flowing at 16 mL/hour. J.T.'s current aPTT value is 128 seconds (goal 60–80 seconds). Which one of the following is best to recommend regarding this patient's anticoagulation therapy?
   A. Discontinue heparin from the purge solution and initiate intravenous heparin at 800 units/hour.
   B. Decrease the heparin purge concentration to 12,500 units in 500 mL of 5% dextrose.
   C. Continue the current regimen and recheck an aPTT value in 6 hours.
   D. Decrease the Impella purge flow rate to 10 mL/hour.

4. A 45-year-old man (weight 72 kg) has an acute anterior STEMI with severe refractory cardiogenic shock requiring TandemHeart support. He is currently receiving an infusate of 45,000 units of heparin in 500 mL of saline at 10 mL/hour. His aPTT 6 hours after arriving in the ICU is 65 seconds. Which one of the following recommendations would be most appropriate for this patient?
   A. Discontinue heparin from the infusate and initiate intravenous heparin 900 units/hour.
   B. Add intravenous heparin at 300 units/hour to the patient's current regimen.
   C. Continue the current regimen and recheck an aPTT value in 6 hours.
   D. Decrease the saline infusate rate to 6 mL/hour.

5. A 65-year-old woman with a history of stage D ischemic cardiomyopathy is postoperative day 2 from a HeartMate III implantation. The patient is clinically stable and has been tolerating intravenous heparin for several days with no signs of hemorrhage. The medical team wants to initiate oral antithrombotic therapy. Which one of the following is best to recommend for this patient according to the current manufacturer's guidelines?
   A. Aspirin 325 mg daily, warfarin INR target 2.5–3.5
   B. Aspirin 325 mg daily, warfarin INR target 1.5–1.9
   C. Aspirin 81 mg daily, warfarin INR target 2.0–3.0
   D. Aspirin 325 mg daily, warfarin INR target 1.5–1.9

6. Which one of the following continuous-flow left ventricular assist device (CF-LVAD) recipients with suspected RV failure would most benefit from inhaled iloprost therapy?
   A. PCWP elevated, PVR elevated, device flow low, blood pressure low
   B. PCWP low, PVR elevated, device flow low, blood pressure low
   C. PCWP low, PVR normal, device flow low, blood pressure low
   D. PCWP elevated, PVR normal, device flow low, blood pressure elevated
7. A 76-year-old man with a history of ischemic cardiomyopathy has a HeartMate II device implantation. His postoperative course is uncomplicated, and he remains in good health for 8 months until he presents with fatigue and melenic stools. He undergoes upper and lower GI scoping, during which arteriovenous malformations are diagnosed and treated with argon laser coagulation. Which one of the following medications would most accurately be considered first line for secondary prevention of GI bleeding?

A. Lisinopril  
B. Octreotide  
C. Thalidomide  
D. Danazol

8. A 68-year-old woman with a HeartWare HVAD presents with sudden-onset epistaxis. This is her third episode in the past month, and at this admission, the team contacts the otolaryngology team for possible nasal packing. In the meantime, the patient has ongoing epistaxis. Her INR is 2.9, and the team is considering anticoagulation reversal. Which one of the following is best to recommend for this patient?

A. Administer 4-factor prothrombin complex concentrates (PCCs) with intravenous vitamin K.  
B. Administer 3-factor PCCs with intravenous vitamin K.  
C. Administer fresh frozen plasma with intravenous vitamin K.  
D. Continue with supportive care with no anticoagulation reversal.

9. A 32-year-old man presents with a history of non-ischemic dilated cardiomyopathy after HeartMate II implantation. His operative course is uncomplicated, and the team asks for your input as the clinical pharmacist in devising the patient’s postoperative antibiotic regimen. Of note, his MRSA nasal swab is negative, indicating that he is not colonized with this organism. Which one of the following regimens would be most appropriate for this patient?

A. Cefazolin plus levofloxacin plus fluconazole  
B. Cefazolin plus vancomycin  
C. Cefazolin  
D. Cefazolin plus rifampin plus fluconazole

10. A 65-year-old man with a history of ischemic dilated cardiomyopathy is now postoperative day 2 from HeartWare HVAD implantation. Surgical hemostasis has been achieved, and the team wants to initiate a thromboprophylactic regimen. The patient’s CrCl is 62 mL/minute. The patient was taking warfarin 5 mg daily for atrial fibrillation before his surgery. No genotype data are available regarding his warfarin sensitivity. The patient has not been initiated on any new medications that interact with warfarin. Which one of the following is best to recommend for this patient?

A. Aspirin 325 mg daily, dabigatran 75 mg twice daily  
B. Aspirin 325 mg daily, warfarin 5 mg daily  
C. Aspirin 81 mg daily, warfarin 5 mg daily  
D. Aspirin 325 mg daily, warfarin 2.5 mg daily

Questions 11–13 pertain to the following case.

M.J. is a 54-year-old man (weight 85 kg) with a medical history of hypertension and osteoarthritis. While recovering from knee arthroplasty (postoperative day 4), M.J. has a cardiac arrest (pulseless electrical activity). Before this arrest, he took enoxaparin 40 mg daily for deep venous thrombosis prophylaxis. The medical team begins administering advanced cardiac life support and contacts the ECMO team to initiate VA ECMO (ECPR). After several rounds of CPR, he has received two doses of epinephrine 1-mg intravenous push, and on rhythm checks, the patient has sinus tachycardia, still without return of spontaneous circulation. The team placing the cannulas asks you to initiate anticoagulation therapy for the ECMO.

11. Which one of the following is best to recommend for M.J.?

A. Bivalirudin 0.75-mg/kg intravenous bolus  
B. Enoxaparin 1 mg/kg subcutaneously once  
C. Unfractionated heparin 8500-unit intravenous bolus  
D. Unfractionated heparin 5000 units subcutaneously once

12. After initiation of ECMO support, M.J. is initiated on dopamine 5 mcg/kg/minute to enhance pulsatility and maintain MAP greater than 60 mm Hg. Since initiation, he has become more hypertensive with a MAP greater than 100 mm Hg. The team is having difficulty tapering dopamine while maintaining pulsatility. Which one of the following is best to recommend for M.J. to eliminate the vasoconstrictive effects of dopamine?

A. Start epinephrine and simultaneously taper dopamine.  
B. Start milrinone and begin tapering dopamine in 2 hours.  
C. Start norepinephrine and simultaneously taper dopamine.  
D. Discontinue dopamine; there is no need to maintain pulsatility in a patient receiving VA ECMO.

13. After 3 days of ECMO support, the heparin infusion for M.J. has been titrated to 38 units/kg/hour. The team is concerned that M.J. is becoming volume overloaded, and his heparin drip is infusing at 65 mL/hour (50 unit/mL concentration). An antithrombin functional assay shows 15% normal function. Which one of the following
is best to recommend regarding antithrombin replacement for M.J.?

A. Administer cryoprecipitate.
B. Administer fresh frozen plasma.
C. Administer recombinant antithrombin.
D. No replacement is indicated.

14. A 65-year-old white man with ischemic cardiomyopathy is accepted for transplantation. His complement-dependent cytotoxicity and calculated panel-reactive antibodies are both zero, and his crossmatch is negative at the time of transplantation. The patient receives the heart of a 45-year-old man. One week later, tapering of isoproterenol and epinephrine results in decreases in his heart rate from 100–110 beats/minute to 75–80 beats/minute with an accompanying decrease in his cardiac index from 2.5 L/minute/m² to 1.9 L/minute/m². Which one of the following is best to recommend for this patient?

A. Goal rate less than 60 beats/minute; current heart rate will improve diastolic filling and cardiac output.
B. Goal rate 70–80 beats/minute; the patient is likely becoming vasodilated, explaining the decrease in cardiac index.
C. Goal rate 80–90 beats/minute; the team should initiate RV pacing to optimize the goal heart rate and improve cardiac synchrony.
D. Goal rate greater than 90 beats/minute; the team should titrate isoproterenol and/or epinephrine and wean more slowly during the next attempt.

15. A 28-year-old woman underwent HT 8 months ago. She was recently given a diagnosis of severe depression and reported that she quit taking her medications about a week earlier, including her immunosuppression. She is now in the ED with symptoms of HF, volume overload, and renal impairment. An echocardiogram reveals biventricular dysfunction, with left ventricular ejection fraction estimated at 25%–30%. The team admitting her to the ICU plans to further evaluate her cardiac function by performing a right heart catheterization and endomyocardial biopsy (EMB). Which one of the following is best to recommend for this patient?

A. No treatment at this time; await results of EMB to determine.
B. Methylprednisolone 1 g intravenously every 24 hours for three doses.
C. Prednisone 2 mg/kg by mouth daily for 3 days.
D. Plasmapheresis followed by 1 g/kg of intravenous immunoglobulin and rituximab 375 mg/m².